The capacity expansion at the plant will help in providing a reliable supply of high-quality products to meet the domestic demand for the company’s products including cardiovascular and anti-diabetes products.
The company said that the expansion will include logistics areas for fully automated material handling, analytical laboratories, and high-speed packaging lines.
Bayer HealthCare CEO Olivier Brandicourt said the expansion of the company’s Beijing site demonstrates its continuous strong commitment to the People’s Republic of China.
"This investment will make Beijing the largest pharmaceuticals packaging site in Bayer HealthCare´s global production network," Brandicourt said.
In Beijing, the company had already established a center for research and development with investments of about EUR100m.
The company has over 7,000 employees and production sites in Beijing, Guangzhou, Chengdu and Qidong.
In 2013, Bayer Group had reported sales of around EUR3.7bn in China where it currently employees more than 13,000 people.
Image: Bayer HealthCare’s research site at Berlin, Germany. Photo: courtesy of Bayer AG.